JP2015526434A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015526434A5 JP2015526434A5 JP2015526845A JP2015526845A JP2015526434A5 JP 2015526434 A5 JP2015526434 A5 JP 2015526434A5 JP 2015526845 A JP2015526845 A JP 2015526845A JP 2015526845 A JP2015526845 A JP 2015526845A JP 2015526434 A5 JP2015526434 A5 JP 2015526434A5
- Authority
- JP
- Japan
- Prior art keywords
- compound according
- dendrimer
- branch
- group
- linker
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 97
- 239000000412 dendrimer Substances 0.000 claims description 50
- 229920000736 dendritic polymer Polymers 0.000 claims description 50
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 42
- 125000005647 linker group Chemical group 0.000 claims description 40
- 230000008685 targeting Effects 0.000 claims description 38
- 239000003795 chemical substances by application Substances 0.000 claims description 37
- 238000000034 method Methods 0.000 claims description 36
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 17
- 125000000217 alkyl group Chemical group 0.000 claims description 14
- 150000001412 amines Chemical class 0.000 claims description 14
- 108010064942 Angiopep-2 Proteins 0.000 claims description 13
- 150000001413 amino acids Chemical group 0.000 claims description 13
- -1 azido-propyl Chemical group 0.000 claims description 13
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims description 10
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 10
- WGYKZJWCGVVSQN-UHFFFAOYSA-N mono-n-propyl amine Natural products CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 claims description 10
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 claims description 7
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 claims description 7
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical class NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 7
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 7
- 239000004472 Lysine Substances 0.000 claims description 7
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims description 7
- UWCPYKQBIPYOLX-UHFFFAOYSA-N benzene-1,3,5-tricarbonyl chloride Chemical compound ClC(=O)C1=CC(C(Cl)=O)=CC(C(Cl)=O)=C1 UWCPYKQBIPYOLX-UHFFFAOYSA-N 0.000 claims description 7
- OOTFVKOQINZBBF-UHFFFAOYSA-N cystamine Chemical compound CCSSCCN OOTFVKOQINZBBF-UHFFFAOYSA-N 0.000 claims description 7
- 229940099500 cystamine Drugs 0.000 claims description 7
- 239000012634 fragment Substances 0.000 claims description 7
- WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 claims description 7
- JKANAVGODYYCQF-UHFFFAOYSA-N prop-2-yn-1-amine Chemical compound NCC#C JKANAVGODYYCQF-UHFFFAOYSA-N 0.000 claims description 7
- AOHJOMMDDJHIJH-UHFFFAOYSA-N propylenediamine Chemical compound CC(N)CN AOHJOMMDDJHIJH-UHFFFAOYSA-N 0.000 claims description 7
- PEQHIRFAKIASBK-UHFFFAOYSA-N tetraphenylmethane Chemical compound C1=CC=CC=C1C(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 PEQHIRFAKIASBK-UHFFFAOYSA-N 0.000 claims description 7
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 claims description 6
- 150000002148 esters Chemical class 0.000 claims description 6
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims description 5
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims description 5
- GHWVXCQZPNWFRO-UHFFFAOYSA-N butane-2,3-diamine Chemical compound CC(N)C(C)N GHWVXCQZPNWFRO-UHFFFAOYSA-N 0.000 claims description 5
- 239000002872 contrast media Substances 0.000 claims description 5
- 239000000032 diagnostic agent Substances 0.000 claims description 5
- 229940039227 diagnostic agent Drugs 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- NLVXSWCKKBEXTG-UHFFFAOYSA-M ethenesulfonate Chemical compound [O-]S(=O)(=O)C=C NLVXSWCKKBEXTG-UHFFFAOYSA-M 0.000 claims description 5
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims description 5
- NAQMVNRVTILPCV-UHFFFAOYSA-N hexane-1,6-diamine Chemical compound NCCCCCCN NAQMVNRVTILPCV-UHFFFAOYSA-N 0.000 claims description 5
- 239000012948 isocyanate Substances 0.000 claims description 5
- 150000002513 isocyanates Chemical class 0.000 claims description 5
- 102000039446 nucleic acids Human genes 0.000 claims description 5
- 108020004707 nucleic acids Proteins 0.000 claims description 5
- 150000007523 nucleic acids Chemical class 0.000 claims description 5
- 102000004169 proteins and genes Human genes 0.000 claims description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 5
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 5
- 150000003384 small molecules Chemical class 0.000 claims description 5
- SEEPANYCNGTZFQ-UHFFFAOYSA-N sulfadiazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 SEEPANYCNGTZFQ-UHFFFAOYSA-N 0.000 claims description 5
- 229940124597 therapeutic agent Drugs 0.000 claims description 5
- 150000003573 thiols Chemical class 0.000 claims description 5
- GWIKYPMLNBTJHR-UHFFFAOYSA-M thiosulfonate group Chemical group S(=S)(=O)[O-] GWIKYPMLNBTJHR-UHFFFAOYSA-M 0.000 claims description 5
- OZDGMOYKSFPLSE-UHFFFAOYSA-N 2-Methylaziridine Chemical compound CC1CN1 OZDGMOYKSFPLSE-UHFFFAOYSA-N 0.000 claims description 4
- 108010039918 Polylysine Proteins 0.000 claims description 4
- 229920000962 poly(amidoamine) Polymers 0.000 claims description 4
- 229920000656 polylysine Polymers 0.000 claims description 4
- 230000002194 synthesizing effect Effects 0.000 claims description 4
- 125000005262 alkoxyamine group Chemical group 0.000 claims description 3
- 150000001540 azides Chemical class 0.000 claims description 3
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 2
- 229920000333 poly(propyleneimine) Polymers 0.000 claims description 2
- 125000006308 propyl amino group Chemical group 0.000 claims description 2
- 239000001273 butane Substances 0.000 claims 2
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 claims 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 claims 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims 1
- 235000018417 cysteine Nutrition 0.000 description 24
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 24
- 229910052717 sulfur Inorganic materials 0.000 description 11
- 125000004434 sulfur atom Chemical group 0.000 description 11
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 150000001735 carboxylic acids Chemical class 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 239000000047 product Substances 0.000 description 3
- JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 2
- 150000003923 2,5-pyrrolediones Chemical class 0.000 description 2
- 0 C*CCC(NCCNC(CCN(CCC(NCCNC(CC*)=O)=O)CCNC(C)CCN(CCC*)CCC(NCCN(CCC(NCCNC(CC*)=O)=O)CCC(NCCNC(CC*)=O)=O)=O)=O)=O Chemical compound C*CCC(NCCNC(CCN(CCC(NCCNC(CC*)=O)=O)CCNC(C)CCN(CCC*)CCC(NCCN(CCC(NCCNC(CC*)=O)=O)CCC(NCCNC(CC*)=O)=O)=O)=O)=O 0.000 description 2
- 102100021923 Prolow-density lipoprotein receptor-related protein 1 Human genes 0.000 description 2
- 101710202113 Prolow-density lipoprotein receptor-related protein 1 Proteins 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide group Chemical group [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 2
- FLCQLSRLQIPNLM-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 2-acetylsulfanylacetate Chemical compound CC(=O)SCC(=O)ON1C(=O)CCC1=O FLCQLSRLQIPNLM-UHFFFAOYSA-N 0.000 description 1
- AMLFJZRZIOZGPW-NSCUHMNNSA-N (e)-prop-1-en-1-amine Chemical compound C\C=C\N AMLFJZRZIOZGPW-NSCUHMNNSA-N 0.000 description 1
- WJWCWIMVMYWVNZ-UHFFFAOYSA-N 2-azidohexanoic acid Chemical group CCCCC(C(O)=O)N=[N+]=[N-] WJWCWIMVMYWVNZ-UHFFFAOYSA-N 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261682991P | 2012-08-14 | 2012-08-14 | |
| US61/682,991 | 2012-08-14 | ||
| PCT/CA2013/050621 WO2014026283A1 (en) | 2012-08-14 | 2013-08-14 | Peptide-dendrimer conjugates and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015526434A JP2015526434A (ja) | 2015-09-10 |
| JP2015526434A5 true JP2015526434A5 (enExample) | 2016-10-06 |
Family
ID=50101156
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015526845A Pending JP2015526434A (ja) | 2012-08-14 | 2013-08-14 | ペプチド−デンドリマーコンジュゲート及びその使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US9687561B2 (enExample) |
| EP (1) | EP2885318A4 (enExample) |
| JP (1) | JP2015526434A (enExample) |
| CN (1) | CN104781276A (enExample) |
| AU (1) | AU2013302270A1 (enExample) |
| CA (1) | CA2881602A1 (enExample) |
| WO (1) | WO2014026283A1 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2233156T3 (pl) | 2005-07-15 | 2013-09-30 | Angiochem Inc | Zastosowanie polipeptydów aprotyninowych jako nośników w koniugatach farmaceutycznych |
| EP2346906A4 (en) | 2008-10-15 | 2013-04-24 | Angiochem Inc | CONJUGATES FROM GLP-1 AGONISTS AND THEIR USE |
| JP5759379B2 (ja) | 2008-12-05 | 2015-08-05 | アンジオケム インコーポレーテッド | ニューロテンシンまたはニューロテンシンアナログおよびその使用 |
| EP2885318A4 (en) | 2012-08-14 | 2016-03-30 | Angiochem Inc | PEPTIDE DENDRIMER CONJUGATES AND ITS USES |
| WO2016090495A1 (en) * | 2014-12-11 | 2016-06-16 | Angiochem Inc. | TARGETED α-L-IDURONIDASE CONJUGATES AND USES THEREOF |
| RS64567B1 (sr) * | 2015-02-24 | 2023-10-31 | Hope City | Platforme za skrining hemijski kodiranih prostorno adresiranih biblioteka |
| CA2989400A1 (en) | 2015-06-15 | 2016-12-22 | Angiochem Inc. | Ang1005 for the treatment of leptomeningeal carcinomatosis |
| US11247968B2 (en) * | 2015-09-14 | 2022-02-15 | The Board Of Regents Of The University Of Texas System | Lipocationic dendrimers and uses thereof |
| JP7108306B2 (ja) * | 2015-10-29 | 2022-07-28 | ザ・ジョンズ・ホプキンス・ユニバーシティー | デンドリマー組成物ならびに壊死性腸炎および他の胃腸障害の処置における使用 |
| CN106854231B (zh) * | 2015-12-09 | 2020-08-11 | 中国科学院大连化学物理研究所 | 一种硫巯化多肽的富集方法 |
| US11530243B2 (en) * | 2016-02-18 | 2022-12-20 | Veiove Animal Health Inc. | Non-cleavable substance P conjugates and methods of use thereof |
| PL417159A1 (pl) * | 2016-05-11 | 2017-11-20 | Instytut Biologii Doświadczalnej Im. Marcelego Nenckiego | Koniugaty białka prionowego z dendrymerami do zastosowania w leczeniu choroby Alzheimera |
| WO2017201091A1 (en) * | 2016-05-16 | 2017-11-23 | The Board Of Regents Of The University Of Texas System | COMPOSITIONS FOR THE DELIVERY OF tRNA AS NANOPARTICLES AND METHODS OF USE THEREWITH |
| CN106279635B (zh) * | 2016-08-10 | 2019-01-25 | 同济大学 | 类抗菌肽和囊泡及其制备方法和应用 |
| ES2677242B1 (es) * | 2017-01-31 | 2019-03-27 | Univ Alcala Henares | Nanoconjugados formados por moléculas dendríticas y péptidos como agentes antitumorales frente al cáncer |
| CN110913916A (zh) | 2017-04-27 | 2020-03-24 | 约翰霍普金斯大学 | 用于血管造影的树状聚合物组合物 |
| CA3082121C (en) | 2017-11-10 | 2023-01-24 | The Johns Hopkins University | Dendrimer delivery system and methods of use thereof |
| US12357580B2 (en) | 2018-06-19 | 2025-07-15 | The Board Of Regents Of The University Of Texas System | Lipid nanoparticle compositions for delivery of mRNA and long nucleic acids |
| GB2592505B (en) | 2018-09-04 | 2023-05-03 | Univ Texas | Compositions and methods for organ specific delivery of nucleic acids |
| WO2020051220A1 (en) | 2018-09-04 | 2020-03-12 | The Board of the Regents of the University of Texas System | Compositions and methods for organ specific delivery of nucleic acids |
| US11175228B2 (en) * | 2018-11-28 | 2021-11-16 | Promega Corporation | Reactive peptide labeling |
| CN110170055A (zh) * | 2019-06-04 | 2019-08-27 | 哈尔滨理工大学 | 一种新型双重脑缺血靶向纳米载体材料的制备方法 |
| WO2021046307A1 (en) * | 2019-09-04 | 2021-03-11 | North Carolina State University | Hybridized poly(amidoamine)-amino acid dendrimers |
| AU2020396561A1 (en) | 2019-12-04 | 2022-07-14 | Ashvattha Therapeutics, Inc. | Dendrimer compositions and methods for drug delivery to the eye |
| KR20220164547A (ko) * | 2020-04-06 | 2022-12-13 | 티바 바이오테크 엘엘씨 | 효율적인 핵산 전달을 위한 운반체 |
| CA3208643A1 (en) | 2021-01-18 | 2022-07-21 | Conserv Bioscience Limited | Coronavirus immunogenic compositions, methods and uses thereof |
| WO2024029242A1 (ja) * | 2022-08-05 | 2024-02-08 | 一丸ファルコス株式会社 | 新規ｌｒｐ１結合ペプチド |
| CN117363697A (zh) * | 2023-10-10 | 2024-01-09 | 上海烈冰生物医药科技有限公司 | 一种用于核酸捕获的高密度探针磁珠制备方法 |
| US12491262B2 (en) | 2023-10-31 | 2025-12-09 | Tiba Biotech Llc | Gene delivery agents |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5258499A (en) | 1988-05-16 | 1993-11-02 | Vestar, Inc. | Liposome targeting using receptor specific ligands |
| US5714167A (en) | 1992-06-15 | 1998-02-03 | Emisphere Technologies, Inc. | Active agent transport systems |
| EP0599303A3 (en) | 1992-11-27 | 1998-07-29 | Takeda Chemical Industries, Ltd. | Peptide conjugate |
| WO1996035788A2 (en) | 1995-05-08 | 1996-11-14 | Scios, Inc. | Kunitz type protease inhibitors |
| WO1996039183A1 (en) | 1995-05-31 | 1996-12-12 | Fred Hutchinson Cancer Research Center | Compositions and methods for targeted delivery of effector molecules |
| AU716923B2 (en) | 1996-03-11 | 2000-03-09 | Aerovance, Inc. | Human bikunin |
| WO1997040854A2 (en) | 1996-05-01 | 1997-11-06 | Antivirals Inc. | Polypeptide conjugates for transporting substances across cell membranes |
| IL131655A0 (en) | 1997-03-04 | 2001-01-28 | Bio Technology General Corp | Isolation of tissue specific ligands and their use for targeting pharmaceuticals to organs |
| IL132941A0 (en) | 1997-05-21 | 2001-03-19 | Univ Leland Stanford Junior | Composition and method for enhancing transport across biological membranes |
| US6372250B1 (en) | 2000-04-25 | 2002-04-16 | The Regents Of The University Of California | Non-invasive gene targeting to the brain |
| EP2147679B1 (en) | 2001-07-25 | 2014-06-25 | Raptor Pharmaceutical, Inc. | Compositions for blood-brain barrier transport |
| AU2002347910A1 (en) | 2001-10-16 | 2003-04-28 | Symbiontics Inc. | Methods and compositions for targeting proteins across the blood brain barrier |
| ATE365213T1 (de) | 2002-02-07 | 2007-07-15 | Yissum Res Dev Co | Aminosäuresequenzen die die fähigkeit besitzen, die durchdringung durch eine biologische barriere erleichtern |
| US6881829B2 (en) | 2002-04-26 | 2005-04-19 | Chimeracom, L.L.C. | Chimeric hybrid analgesics |
| ES2368941T3 (es) | 2003-01-06 | 2011-11-23 | Angiochem Inc. | Angiopep-1, compuestos relacionados y utilizaciones correspondientes. |
| AU2003286870A1 (en) | 2003-06-05 | 2005-01-04 | Salk Institute For Biological Studies | Targeting polypeptides to the central nervous system |
| WO2005002515A2 (en) | 2003-06-20 | 2005-01-13 | Biomarin Pharmaceutical Inc. | Delivery of therapeutic compounds to the brain and other tissues |
| US20050026823A1 (en) | 2003-06-20 | 2005-02-03 | Biomarin Pharmaceutical Inc. | Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues |
| US7927811B2 (en) | 2003-08-08 | 2011-04-19 | Proteus Sciences Co., Ltd. | Polypeptides having brain-localizing activity and uses thereof |
| US20050058702A1 (en) | 2003-09-17 | 2005-03-17 | Ben-Sasson Shmuel A. | Compositions capable of facilitating penetration across a biological barrier |
| CA2578205A1 (en) * | 2004-08-25 | 2006-03-30 | The Regents Of The University Of Michigan | Partially acetylated dendrimers and related methods of use |
| US20060078535A1 (en) * | 2004-10-13 | 2006-04-13 | The Regents Of The University Of Michigan | Anticancer compounds and methods |
| RU2408605C2 (ru) | 2005-02-18 | 2011-01-10 | Анджиокем Инк. | Полипептид, способный преодолевать гематоэнцефалический барьер, и его конъюгат |
| US20090016959A1 (en) | 2005-02-18 | 2009-01-15 | Richard Beliveau | Delivery of antibodies to the central nervous system |
| PL2233156T3 (pl) | 2005-07-15 | 2013-09-30 | Angiochem Inc | Zastosowanie polipeptydów aprotyninowych jako nośników w koniugatach farmaceutycznych |
| KR20080042804A (ko) | 2005-07-19 | 2008-05-15 | 더 보드 오브 트러스티즈 오브 더 유니버시티 오브 일리노이 | 뇌혈관장벽을 통하여 뇌 암세포 내로 침투하는 운반제 및이의 이용 방법 |
| US8142781B2 (en) | 2005-10-07 | 2012-03-27 | Armagen Technologies, Inc. | Fusion proteins for blood-brain barrier delivery |
| EP2074142A4 (en) | 2006-10-19 | 2010-10-27 | Angiochem Inc | COMPOUNDS FOR STIMULATING THE FUNCTION OF P-GLYCOPROTEIN AND APPLICATIONS THEREOF |
| CN101815724B (zh) | 2007-05-29 | 2015-02-25 | 安吉奥开米公司 | 用于将轭合至其的试剂递送至组织的抑肽酶样多肽 |
| US9365634B2 (en) | 2007-05-29 | 2016-06-14 | Angiochem Inc. | Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues |
| CA2709635A1 (en) | 2007-12-20 | 2009-07-02 | Angiochem Inc. | Polypeptide-nucleic acid conjugates and uses thereof |
| JP5860698B2 (ja) | 2008-04-18 | 2016-02-16 | アンジオケム，インコーポレーテッド | パクリタキセル、パクリタキセル類似体またはパクリタキセルコンジュゲートの医薬組成物ならびに関連する調製方法および使用方法 |
| EP2346906A4 (en) | 2008-10-15 | 2013-04-24 | Angiochem Inc | CONJUGATES FROM GLP-1 AGONISTS AND THEIR USE |
| JP5705118B2 (ja) | 2008-10-15 | 2015-04-22 | アンジオケム インコーポレーテッド | 薬物送達のためのエトポシドおよびドキソルビシン複合体 |
| JP5759379B2 (ja) | 2008-12-05 | 2015-08-05 | アンジオケム インコーポレーテッド | ニューロテンシンまたはニューロテンシンアナログおよびその使用 |
| US20110288009A1 (en) | 2008-12-05 | 2011-11-24 | Angiochem Inc. | Leptin and leptin analog conjugates and uses thereof |
| BRPI0923283A2 (pt) | 2008-12-05 | 2017-06-06 | Angiochem Inc | conjugados terapêuticos de peptídeo e usos dos mesmos |
| WO2010069074A1 (en) | 2008-12-17 | 2010-06-24 | Universite Du Quebec A Montreal | Membrane type-1 matrix metalloprotein inhibitors and uses thereof |
| US20110318322A1 (en) | 2009-01-12 | 2011-12-29 | Nektar Therapeutics | Conjugates of a Lysosomal Enzyme Moiety and a Water Soluble Polymer |
| EP2421562B1 (en) | 2009-04-20 | 2019-03-13 | Angiochem Inc. | Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog |
| US20100284921A1 (en) | 2009-05-08 | 2010-11-11 | Temple University - Of The Commonwealth System Of Higher Education | Targeted nanoparticles for intracellular cancer therapy |
| US20120196803A1 (en) | 2009-06-11 | 2012-08-02 | Angiochem Inc. | Fusion proteins for delivery of gdnf and bdnf to the central nervous system |
| RU2012103240A (ru) | 2009-07-02 | 2013-08-10 | Ангиокем Инк. | Мультимерные пептидные конъюгаты и их применение |
| PL2453923T3 (pl) | 2009-07-14 | 2016-06-30 | Mayo Found Medical Education & Res | Niekowalencyjne dostarczanie aktywnych czynników przez barierę krew-mózg przy udziale peptydów |
| US20120277158A1 (en) * | 2009-10-06 | 2012-11-01 | Angiochem Inc. | Compositions and methods for the transport of therapeutic agents |
| US8530429B2 (en) | 2009-11-24 | 2013-09-10 | Arch Cancer Therapeutics, Inc. | Brain tumor targeting peptides and methods |
| US9095541B2 (en) | 2009-11-24 | 2015-08-04 | Arch Cancer Therapeutics, Inc. | Brain tumor targeting peptides and methods |
| EP2333074A1 (en) | 2009-12-14 | 2011-06-15 | Robert Steinfeld | Substances and methods for the treatment of lysosmal storage diseases |
| WO2011153642A1 (en) | 2010-06-10 | 2011-12-15 | Angiochem Inc. | Leptin and leptin analog conjugates and fusion proteins and uses thereof |
| RU2013103763A (ru) | 2010-07-02 | 2014-08-10 | Ангиохем Инк. | Короткие и содержащие d-аминокислоты полипептиды для терапевтических конъюгатов и их применения |
| CN102406949B (zh) | 2010-09-21 | 2013-05-29 | 复旦大学 | 一种靶向示踪的多模式诊断纳米影像药物 |
| WO2012037687A1 (en) * | 2010-09-23 | 2012-03-29 | Angiochem Inc. | Therapeutic polypeptides and uses thereof |
| CN102552928A (zh) | 2010-12-19 | 2012-07-11 | 复旦大学 | 一种治疗脑部肿瘤的双级靶向递药系统及其制备方法 |
| CN102614105A (zh) | 2011-01-28 | 2012-08-01 | 复旦大学 | 一种脑靶向载两性霉素b聚合物胶束给药系统 |
| WO2013056096A1 (en) | 2011-10-13 | 2013-04-18 | Angiochem Inc. | Polypeptide-opioid conjugates and uses thereof |
| MX2014006594A (es) | 2011-12-01 | 2015-09-16 | Angiochem Inc | Compuestos de enzimas lisosomales apuntados. |
| EP2785837A4 (en) | 2011-12-01 | 2015-07-01 | Angiochem Inc | TARGETED ENZYMATIC COMPOUNDS AND ITS USES |
| MX2014015551A (es) | 2012-06-15 | 2016-09-19 | Angiochem Inc | Compuestos iduronidasa apuntados. |
| AU2013302273A1 (en) | 2012-08-14 | 2015-02-19 | Angiochem Inc. | Conjugates including an antibody moiety, a polypeptide that traverses the blood-brain barrier, and a cytotoxin |
| EP2885318A4 (en) | 2012-08-14 | 2016-03-30 | Angiochem Inc | PEPTIDE DENDRIMER CONJUGATES AND ITS USES |
| MX377795B (es) | 2012-11-12 | 2025-03-11 | Angiochem Inc | Conjugados de polipeptido derivado de aprotinina-anticuerpo. |
| GB201220474D0 (en) | 2012-11-14 | 2012-12-26 | Sagetis Biotech Sl | Polypeptides |
| WO2014082184A1 (en) | 2012-11-30 | 2014-06-05 | Angiochem Inc. | Targeted iduronate-2-sulfatase compounds |
| WO2014194429A1 (en) | 2013-06-06 | 2014-12-11 | Angiochem Inc. | Targeted enzyme compounds and uses thereof |
| WO2014194428A1 (en) | 2013-06-06 | 2014-12-11 | Angiochem Inc. | Targeted heparan sulfatase compounds |
-
2013
- 2013-08-14 EP EP13829574.6A patent/EP2885318A4/en not_active Withdrawn
- 2013-08-14 WO PCT/CA2013/050621 patent/WO2014026283A1/en not_active Ceased
- 2013-08-14 US US14/422,165 patent/US9687561B2/en not_active Expired - Fee Related
- 2013-08-14 CA CA2881602A patent/CA2881602A1/en not_active Abandoned
- 2013-08-14 AU AU2013302270A patent/AU2013302270A1/en not_active Abandoned
- 2013-08-14 JP JP2015526845A patent/JP2015526434A/ja active Pending
- 2013-08-14 CN CN201380053703.4A patent/CN104781276A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015526434A5 (enExample) | ||
| JP7417432B2 (ja) | 新規リンカー、その製造方法およびその応用 | |
| JP2012533587A5 (enExample) | ||
| KR101617790B1 (ko) | 치료, 진단과 실험적 혼합물들의 운반을 위한 공학적으로 가변된 나노입자 및 치료용 관련 조성물 | |
| Okuda et al. | PEGylated lysine dendrimers for tumor-selective targeting after intravenous injection in tumor-bearing mice | |
| JP7291624B2 (ja) | アルファ－ｖベータ－６インテグリンリガンド及びその使用 | |
| JP2013530993A5 (enExample) | ||
| JP2021502810A5 (enExample) | ||
| JP2015519339A5 (enExample) | ||
| Pisal et al. | Permeability of surface-modified polyamidoamine (PAMAM) dendrimers across Caco-2 cell monolayers | |
| Wender et al. | Dendrimeric molecular transporters: synthesis and evaluation of tunable polyguanidino dendrimers that facilitate cellular uptake | |
| JP2014520120A5 (enExample) | ||
| MX2012011515A (es) | Entidades quimicas simples novedosas y metodos de suministro de oligonucleotidos. | |
| JP2017509594A5 (enExample) | ||
| WO2011154331A1 (en) | Polymers for delivery of nucleic acids | |
| JP2011530537A5 (enExample) | ||
| RU2012157167A (ru) | Полифункциональные антительные конъюгаты | |
| CN103417480A (zh) | 一种靶向整合素受体的新型多肽修饰的肿瘤靶向脂质体 | |
| WO2015165413A1 (zh) | 一种新型的稳定型抗体药物耦联物及其制备方法和用途 | |
| JP2008515889A5 (enExample) | ||
| AU2006270566A1 (en) | Method of conjugating therapeutic compounds to cell targeting moieties via metal complexes | |
| Tang et al. | Peptide-functionalized nanoparticles for brain-targeted therapeutics | |
| RU2017129729A (ru) | Конъюгаты антитело-уреаза для терапевтических целей | |
| JP2015512247A5 (enExample) | ||
| JP7644105B2 (ja) | 核酸治療薬のための腫瘍標的化ポリペプチドナノ粒子送達システム |